Studying the Role of C5-Inhibition Therapy in Scleroderma Renal Crisis-Induced Thrombotic Microangiopathy – A Review of Literature

伊库利珠单抗 医学 血栓性微血管病 美罗华 硬皮病(真菌) 内科学 血浆置换术 胃肠病学 免疫学 补体系统 疾病 抗体 接种 淋巴瘤
作者
Larabe Farrukh,Virginia Steen,Lee Shapiro,Sameer Mehta
出处
期刊:Seminars in Arthritis and Rheumatism [Elsevier BV]
卷期号:63: 152256-152256 被引量:12
标识
DOI:10.1016/j.semarthrit.2023.152256
摘要

The pathogenesis of scleroderma renal crisis (SRC) remains poorly understood but a growing body of evidence suggests that activation of the complement system may be involved in the disease. Recent studies have shown that Eculizumab (monoclonal antibody directed against the complement component C5) is effective in treating patients with SRC who present with symptoms of thrombotic microangiopathy (SRC-TMA). In this study, we conducted a systematic review to characterize the published experience of the presentation and outcome of patients with SRC who were treated with C5 inhibitor, Eculizumab. A literature search was conducted from inception to December 2022 using Medical Subject Headings (MeSH) terms for ‘scleroderma’, ‘scleroderma renal crisis, and ‘Eculizumab’. We included case reports, case series, and observational studies which reported the use of Eculizumab with or without Angiotensin-converting enzyme inhibitors (ACE-I) for the treatment of scleroderma renal crisis (SRC) in patients with systemic sclerosis. The study included 17 patients, all of whom were treated with Eculizumab. Additionally, the use of ACE-I was reported in 11/17 (64.7%) patients. Further, plasmapheresis was used in 9/17 (52.9%), steroids in 5/17 (29.4%), cyclophosphamide in 3/17 (17.6%), calcium channel blockers in 3/17 (17.6%), and Rituximab in 3/17 (17.6%) patients. Renal replacement therapy was required in 11/17 (64.7%) patients. 14/17 patients (82.3%) were reported to have clinical (renal or hematologic) improvement with Eculizumab therapy (Table 1). These findings should prompt testing on a larger cohort of SRC-TMA patients. This would help us determine whether aggressive treatment combining ACE-I and Eculizumab can target the various underlying endothelial, inflammatory, and immunologic mechanisms involved in SRC-TMA, and improve patient outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xz完成签到 ,获得积分10
刚刚
刚刚
1618发布了新的文献求助10
刚刚
1秒前
搜集达人的应助被xtc采纳,获得10
2秒前
zorro3574完成签到,获得积分10
5秒前
5秒前
踏实的盼柳的应助被WaNgBO采纳,获得10
5秒前
5秒前
6秒前
BANANA发布了新的文献求助10
6秒前
王乐安完成签到,获得积分10
6秒前
Able完成签到 ,获得积分10
7秒前
时尚篮球完成签到,获得积分10
7秒前
7秒前
赘婿的应助被we采纳,获得10
9秒前
行者发布了新的文献求助10
9秒前
kkm发布了新的文献求助10
10秒前
10秒前
韶枫完成签到,获得积分10
10秒前
滴滴答答发布了新的文献求助10
10秒前
kakak完成签到,获得积分10
11秒前
哈哈哈完成签到 ,获得积分10
11秒前
落幕无悔完成签到 ,获得积分10
11秒前
蜜雪冰城完成签到,获得积分10
12秒前
乌黑的眼圈完成签到,获得积分10
12秒前
12秒前
xtc发布了新的文献求助10
13秒前
14秒前
14秒前
YanChengHan完成签到,获得积分10
15秒前
在水一方的应助被陆羽泡的茶采纳,获得10
15秒前
致恒夏发布了新的文献求助10
15秒前
lc发布了新的文献求助10
16秒前
Aj发布了新的文献求助10
17秒前
风吹麦浪的应助被刘乐会采纳,获得10
17秒前
乐观地sail发布了新的文献求助10
17秒前
18秒前
传奇3的应助被11111采纳,获得10
18秒前
李若菲完成签到,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158017
求助须知:如何正确求助?哪些是违规求助? 9553900
关于积分的说明 21716555
捐赠科研通 7747340
什么是DOI,文献DOI怎么找? 3426934
关于科研通互助平台的介绍 2551639
邀请新用户注册赠送积分活动 2471005